Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Glucotrack Inc. (NASDAQ: GCTK) has announced the formation of a Patient Advisory Board (PAB) to enhance the development of its long-term implantable Continuous Blood Glucose Monitor (CBGM). Following their successful first-in-human clinical study, the PAB will include individuals with direct diabetes experience to provide insights on product development and commercialization strategies.
The company's CBGM technology is designed as a long-term implantable system with no wearable component, offering up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, potentially eliminating typical lag times in readings. The inaugural PAB meeting was held on May 3, 2025, with regular meetings planned to gather ongoing patient feedback.
Glucotrack Inc. (NASDAQ: GCTK) ha annunciato la creazione di un Patient Advisory Board (PAB) per migliorare lo sviluppo del suo monitor continuo del glucosio nel sangue (CBGM) impiantabile a lungo termine. Dopo il successo del primo studio clinico sull'uomo, il PAB includerà persone con esperienza diretta nel diabete per fornire suggerimenti sullo sviluppo del prodotto e sulle strategie di commercializzazione.
La tecnologia CBGM dell'azienda è progettata come un sistema impiantabile a lungo termine senza componenti indossabili, offrendo fino a tre anni di monitoraggio continuo. A differenza dei monitor tradizionali che misurano il glucosio dal fluido interstiziale, il dispositivo Glucotrack misura direttamente dal sangue, eliminando potenzialmente i ritardi tipici nelle letture. La prima riunione del PAB si è tenuta il 3 maggio 2025, con incontri regolari previsti per raccogliere feedback continui dai pazienti.
Glucotrack Inc. (NASDAQ: GCTK) ha anunciado la formación de un Patient Advisory Board (PAB) para mejorar el desarrollo de su monitor continuo de glucosa en sangre implantable a largo plazo (CBGM). Tras el exitoso estudio clínico inicial en humanos, el PAB incluirá a personas con experiencia directa en diabetes para aportar ideas sobre el desarrollo del producto y las estrategias de comercialización.
La tecnología CBGM de la compañía está diseñada como un sistema implantable a largo plazo sin componentes portátiles, ofreciendo hasta tres años de monitoreo continuo. A diferencia de los monitores tradicionales que miden la glucosa en el fluido intersticial, el dispositivo de Glucotrack mide directamente en la sangre, eliminando potencialmente los retrasos típicos en las lecturas. La reunión inaugural del PAB se llevó a cabo el 3 de mayo de 2025, con reuniones regulares planificadas para recopilar comentarios continuos de los pacientes.
Glucotrack Inc. (NASDAQ: GCTK)는 장기 이식형 연속 혈당 모니터(CBGM) 개발을 강화하기 위해 환자 자문 위원회(PAB)를 구성했다고 발표했습니다. 첫 번째 인간 대상 임상 시험의 성공을 바탕으로 PAB에는 당뇨병 경험이 있는 개인들이 포함되어 제품 개발 및 상업화 전략에 대한 통찰을 제공할 예정입니다.
회사의 CBGM 기술은 착용 부품이 없는 장기 이식형 시스템으로 설계되어 최대 3년간 연속 모니터링이 가능합니다. 기존의 간질액에서 포도당을 측정하는 모니터와 달리, Glucotrack의 장치는 혈액에서 직접 측정하여 일반적인 측정 지연 시간을 없앨 수 있습니다. 첫 PAB 회의는 2025년 5월 3일에 개최되었으며, 환자 피드백을 지속적으로 수집하기 위해 정기적인 회의가 예정되어 있습니다.
Glucotrack Inc. (NASDAQ: GCTK) a annoncé la création d'un Patient Advisory Board (PAB) afin d'améliorer le développement de son moniteur continu de glycémie implantable à long terme (CBGM). Suite au succès de leur première étude clinique sur l'humain, le PAB comprendra des personnes ayant une expérience directe du diabète pour apporter des perspectives sur le développement du produit et les stratégies de commercialisation.
La technologie CBGM de l'entreprise est conçue comme un système implantable à long terme sans composant portable, offrant jusqu'à trois ans de surveillance continue. Contrairement aux moniteurs traditionnels qui mesurent la glycémie dans le liquide interstitiel, l'appareil Glucotrack mesure directement dans le sang, éliminant potentiellement les délais habituels dans les lectures. La première réunion du PAB a eu lieu le 3 mai 2025, avec des réunions régulières prévues pour recueillir les retours continus des patients.
Glucotrack Inc. (NASDAQ: GCTK) hat die Gründung eines Patient Advisory Board (PAB) bekanntgegeben, um die Entwicklung seines langfristig implantierbaren kontinuierlichen Blutzuckermonitors (CBGM) zu verbessern. Nach der erfolgreichen ersten klinischen Studie am Menschen wird das PAB Personen mit direkter Erfahrung im Umgang mit Diabetes umfassen, um Einblicke in die Produktentwicklung und Vermarktungsstrategien zu geben.
Die CBGM-Technologie des Unternehmens ist als langfristig implantierbares System ohne tragbare Komponenten konzipiert und bietet bis zu drei Jahre kontinuierliche Überwachung. Im Gegensatz zu herkömmlichen Monitoren, die den Glukosewert aus der interstitiellen Flüssigkeit messen, misst das Gerät von Glucotrack direkt im Blut, wodurch typische Verzögerungen bei den Messwerten potenziell entfallen. Das erste Treffen des PAB fand am 3. Mai 2025 statt, regelmäßige Treffen sind geplant, um fortlaufendes Patientenfeedback zu sammeln.
- Formation of Patient Advisory Board demonstrates commitment to user-centered product development
- CBGM technology offers up to 3 years of continuous monitoring without wearable components
- Direct blood glucose measurement could eliminate lag time present in traditional monitoring systems
- Successful completion of first-in-human clinical study indicates progress in development
- Product is still in investigational phase with no clear timeline for commercialization
- Long-term implantable devices may carry additional regulatory hurdles and safety considerations
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
RUTHERFORD, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the formation of a Patient Advisory Board (PAB) comprised of leading patient voices and advocates within the diabetes community.
Following the successful completion of the Company's first-in-human clinical study, the PAB includes individuals with firsthand experiences and understanding of the impact diabetes management has on daily living. Establishing the PAB aims to keep patients’ insights at the forefront of Glucotrack’s development plans for its long-term implantable Continuous Blood Glucose Monitor (CBGM).
“Similar to scientific or medical advisory boards, we believe that having a patient advisory board is critical to the successful development of our groundbreaking technology,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “This advisory board will allow us to incorporate authentic patient perspectives on an ongoing basis, helping ensure that our innovations address real-world challenges faced by people with diabetes. We look forward to partnering with this group to gain additional insights that will help us create the first CBGM developed WITH people with diabetes FOR people with diabetes.”
The inaugural PAB meeting was held on May 3, 2025. The insights and feedback from this board will make a significant impact on every stage of the CBGM, from clinical to commercial. The board will convene regularly to provide insights on living with diabetes, current management challenges and feedback on Glucotrack’s product development and commercialization strategies.
Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information about Glucotrack’s CBGM technology, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
What is Glucotrack's GCTK new Continuous Blood Glucose Monitor technology?
How is Glucotrack's GCTK blood glucose monitor different from traditional CGMs?
What is the purpose of Glucotrack's (GCTK) new Patient Advisory Board?
Has Glucotrack's (GCTK) blood glucose monitor been approved by the FDA?
When did Glucotrack (GCTK) complete its first-in-human clinical study?
